The impact of fibroblast growth factor-23 on the cardiovascular system in chronic kidney disease

被引：1

作者：

Lee, Gavin ^{[1
]}

Krishnasamy, Rathika ^{[1
,2
]}

Hawley, Carmel M. ^{[1
,2
,3
]}

Johnson, David W. ^{[1
,2
,3
]}

机构：

[1] Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia

[2] Univ Queensland, Sch Med, Brisbane, Qld, Australia

[3] Translat Res Inst, Brisbane, Qld, Australia

来源：

EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM | 2015年 / 10卷 / 06期

关键词：

cardiovascular disease; chronic kidney disease; endothelial function; fibroblast growth factor-23; klotho; left ventricular hypertrophy; secondary hyperparathyroidism; vascular calcification;

D O I：

10.1586/17446651.2015.1079124

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease is associated with an accelerated risk of cardiovascular (CV) mortality. Seminal work over the last decade has identified abnormal bone metabolism as an important modulator of the increased CV burden in this cohort. In particular, FGF23, a phosphaturic hormone with serum levels found to be markedly elevated in chronic kidney disease, is independently associated with increased risks of all-cause mortality and CV events. This editorial will discuss the proposed mechanisms linking FGF23 to CV disease in chronic kidney disease, namely, direct cardiac myocyte toxicity, endothelial dysfunction and vascular calcification.

引用

页码：565 / 568

页数：4

共 29 条

[21] FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability [J].

Silswal, Neerupma ;

Touchberry, Chad D. ;

Daniel, Dorothy R. ;

McCarthy, Darla L. ;

Zhang, Shiqin ;

Andresen, Jon ;

Stubbs, Jason R. ;

Wacker, Michael J. .

AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2014, 307 (05) :E426-E436

[22] Fibroblast growth factor 23 [J].

Smith, Edward R. ;

McMahon, Lawrence P. ;

Holt, Stephen G. .

ANNALS OF CLINICAL BIOCHEMISTRY, 2014, 51 (02) :203-227

[23] Chronic kidney disease and mortality risk: A systematic review [J].

Tonelli, Marcello ;

Wiebe, Natasha ;

Culleton, Bruce ;

House, Andrew ;

Rabbat, Chris ;

Fok, Mei ;

McAlister, Finlay ;

Garg, Amit X. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (07) :2034-2047

[24]

USRDS, 2012, ANN DAT REP

[25] Fibroblast growth factor (FGF)-23 and fetuin-A in calcified carotid atheroma [J].

Voigt, Mathias ;

Fischer, Dagmar-Christiane ;

Rimpau, Max ;

Schareck, Wolfgang ;

Haffner, Dieter .

HISTOPATHOLOGY, 2010, 56 (06) :775-788

[26] Update on fibroblast growth factor 23 in chronic kidney disease [J].

Wolf, Myles .

KIDNEY INTERNATIONAL, 2012, 82 (07) :737-747

[27] Fibroblast growth factor 23 and risk of all-cause mortality and cardiovascular events: A meta-analysis of prospective cohort studies [J].

Xiao, Yunjun ;

Luo, Xianru ;

Huang, Wei ;

Zhang, Jinzhou ;

Peng, Chaoqiong .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 174 (03) :824-828

[28] Soluble Klotho Protects against Uremic Cardiomyopathy Independently of Fibroblast Growth Factor 23 and Phosphate [J].

Xie, Jian ;

Yoon, Joonho ;

An, Sung-Wan ;

Kuro-o, Makoto ;

Huang, Chou-Long .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 26 (05) :1150-1160

[29] FGF-23 and vascular dysfunction in patients with stage 3 and 4 chronic kidney disease [J].

Yilmaz, Mahmut I. ;

Sonmez, Alper ;

Saglam, Mutlu ;

Yaman, Halil ;

Kilic, Selim ;

Demirkaya, Erkan ;

Eyileten, Tayfun ;

Caglar, Kayser ;

Oguz, Yusuf ;

Vural, Abdulgaffar ;

Yenicesu, Mujdat ;

Zoccali, Carmine .

KIDNEY INTERNATIONAL, 2010, 78 (07) :679-685

← 1 2 3 →